+++
title = "ATP"
description = "Adenosintrifosf\u00e1t - univerz\u00e1ln\u00ed energetick\u00e1 m\u011bna bu\u0148ky a kl\u00ed\u010dov\u00fd neurotransmiter"
date = 2024-01-15
updated = 2024-01-15
draft = false
[taxonomies]
categories = ["nukleotidy", "neurotransmitery", "purinov\u00e9-sign\u00e1ly"]
tags = ["ATP", "energie", "purinergn\u00ed-signalizace", "P2X", "P2Y", "synaptick\u00fd-p\u0159enos", "bolest", "glie"]
[extra]
toc = true
math = true
mermaid = true
scientific_level = "advanced"
molecule_formula = "C10H16N5O13P3"
molecular_weight = 507.18
cas_number = "56-65-5"
iupac_name = "adenosin-5'-trifosf\u00e1t"
+++

# Adenosintrifosf\u00e1t (ATP)

Adenosintrifosf\u00e1t (ATP) p\u0159edstavuje fundamenta\u00e1ln\u00ed molekulu \u017eivota - univerz\u00e1ln\u00ed
energetickou m\u011bnu, kter\u00e1 pohán\u00ed prakticky v\u0161echny bun\u011b\u010dn\u00e9 procesy. Krom\u011b sv\u00e9 prim\u00e1rn\u00ed
role jako nosi\u010de energie v\u0161ak ATP funguje tak\u00e9 jako v\u00fdznamn\u00fd neurotransmiter a sign\u00e1ln\u00ed
molekula v nervov\u00e9m syst\u00e9mu. Tento dualisimus \u010din\u00ed z ATP jednu z nejuniversa\u00e1ln\u011bj\u0161\u00edch
a nejd\u016fle\u017eit\u011bj\u0161\u00edch molekul v biologii.

## Chemick\u00e1 struktura a vlastnosti

### Z\u00e1kladn\u00ed architektura molekuly

ATP je nukleotid slo\u017een\u00fd ze t\u0159\u00ed kl\u00ed\u010dov\u00fdch komponent:

1. **Adenin** - purinov\u00e1 b\u00e1ze obsahuj\u00edc\u00ed dva spojen\u00e9 heterocyklick\u00e9 kruhy
   (pyrimidinov\u00fd a imidazolov\u00fd), kter\u00e1 zaji\u0161\u0165uje specifitu rozpozn\u00e1v\u00e1n\u00ed enzymy
2. **Rib\u00f3za** - p\u011btiuhl\u00edkat\u00fd cukr (pentosa) v furan\u00f3zov\u00e9 form\u011b, kter\u00fd spojuje
   adenin s fosfátov\u00fdmi skupinami
3. **Trifosfátov\u00fd \u0159et\u011bzec** - t\u0159i fosfátov\u00e9 skupiny (alfa, beta, gama) spojen\u00e9
   vysoce energetick\u00fdmi fosfoanhyridov\u00fdmi vazbami

### Energetika fosfátov\u00fdch vazeb

Energie ulo\u017een\u00e1 v ATP poch\u00e1z\u00ed p\u0159edev\u0161\u00edm z fosfoanhyridov\u00fdch vazeb mezi
fosfátov\u00fdmi skupinami:

- **Vazba P~P (beta-gama)**: \u0394G\u00b0' = -30,5 kJ/mol
- **Vazba P~P (alfa-beta)**: \u0394G\u00b0' = -30,5 kJ/mol
- **Vazba P-O (adenosin-alfa)**: \u0394G\u00b0' = -14,2 kJ/mol (esterov\u00e1 vazba)

Hydrol\u00fdza ATP na ADP a anorganick\u00fd fosfát (Pi) uvol\u0148uje standardn\u011b
p\u0159ibli\u017en\u011b 30,5 kJ/mol, av\u0161ak za fyziologick\u00fdch podm\u00ednek v bu\u0148ce m\u016f\u017ee
tato hodnota dos\u00e1hnout a\u017e 50-54 kJ/mol d\u00edky koncentra\u010dn\u00edm gradient\u016fm.

### Konformace a komplexace s ionty

ATP v biologick\u00fdch syst\u00e9mech existuje p\u0159ev\u00e1\u017en\u011b jako komplex s ho\u0159e\u010dnat\u00fdmi
ionty (Mg\u00b2\u207a-ATP). Tato komplexace je kl\u00ed\u010dov\u00e1 pro:

- Stabilizaci negativn\u011b nabit\u00e9ho fosfátov\u00e9ho \u0159et\u011bzce
- Spr\u00e1vnou orientaci substrátu v aktivn\u00edm m\u00edst\u011b enzym\u016f
- Modulaci reak\u010dn\u00ed kinetiky ATP\u00e1z

## Biosyn\u00e9za ATP

### Oxidativn\u00ed fosforylace

Prim\u00e1rn\u00ed zdroj ATP v aerob\u00edch organism\u016f p\u0159edstavuje oxidativn\u00ed fosforylace
prob\u00edha\u00edjc\u00ed na vnit\u0159n\u00ed mitochondri\u00e1ln\u00ed membráne:

1. **Elektronov\u00fd transportn\u00ed \u0159et\u011bzec (ETC)**
   - Komplex I (NADH dehydrogen\u00e1za): p\u0159en\u00e1\u0161\u00ed elektrony z NADH
   - Komplex II (sukcinát dehydrogen\u00e1za): p\u0159en\u00e1\u0161\u00ed elektrony z FADH\u2082
   - Komplex III (cytochrom bc\u2081): p\u0159en\u00e1\u0161\u00ed elektrony na cytochrom c
   - Komplex IV (cytochrom c oxid\u00e1za): fin\u00e1ln\u00ed p\u0159enos na kysl\u00edk

2. **Chemiosmotick\u00e1 teorie**
   - Prototn\u00fd gradient (\u0394pH ~ 0,5-1,0; \u0394\u03c8 ~ 150-180 mV)
   - Protonmotivn\u00ed s\u00edla: \u0394p = \u0394\u03c8 - 2,3(RT/F)\u0394pH
   - ATP synta\u00e1za (F\u2080F\u2081-ATP\u00e1za) - rota\u010dn\u00ed motor

3. **V\u00fdte\u017enost**
   - Teoreticky: ~2,5 ATP/NADH a ~1,5 ATP/FADH\u2082
   - Prakticky: ni\u017e\u0161\u00ed kv\u016fli protonov\u00e9mu \u00faniku a transportn\u00edm n\u00e1klad\u016fm

### Substrátov\u00e1 fosforylace

P\u0159\u00edm\u00e1 syntéza ATP bez protonov\u00e9ho gradientu:

- **Glykolytick\u00e1 dráha**:
  - 1,3-bisfosfoglycer\u00e1t \u2192 3-fosfoglycer\u00e1t (fosfogycer\u00e1tkin\u00e1za)
  - Fosfoenolpyruv\u00e1t \u2192 pyruv\u00e1t (pyruv\u00e1tkin\u00e1za)

- **Citr\u00e1tov\u00fd cyklus**:
  - Sukcinyl-CoA \u2192 sukcinát (sukcinyl-CoA syntet\u00e1za) - tvo\u0159\u00ed GTP

### Adenyl\u00e1tkin\u00e1zov\u00e1 reakce

Klí\u010dov\u00e1 rovnov\u00e1\u017en\u00e1 reakce pro údr\u017ebu energetick\u00e9ho n\u00e1boje:

```
2 ADP \u21c4 ATP + AMP
```

Tato reakce umo\u017e\u0148uje rychlou regeneraci ATP p\u0159i vysoké spot\u0159eb\u011b energie
a sou\u010dasn\u011b generuje AMP jako sign\u00e1l n\u00edzk\u00e9 energie pro aktivaci AMPK.

## ATP jako univerz\u00e1ln\u00ed energetick\u00e1 m\u011bna

### Mechanismy p\u0159enosu energie

ATP zaji\u0161\u0165uje energetickou spojku mezi exergonick\u00fdmi a endergonick\u00fdmi
procesy prost\u0159ednictv\u00edm n\u011bkolika mechanismů:

1. **P\u0159\u00edm\u00e1 hydrol\u00fdza**
   - Svalov\u00e1 kontrakce (myozinov\u00e1 ATP\u00e1za)
   - Aktivn\u00ed transport (Na\u207a/K\u207a-ATP\u00e1za, Ca\u00b2\u207a-ATP\u00e1za)

2. **Fosforylace substrát\u016f**
   - Aktivace metabolit\u016f (glukokina\u00e1za, hexokin\u00e1za)
   - Sign\u00e1ln\u00ed kask\u00e1dy (proteinkin\u00e1zy)

3. **Adenylylace**
   - Aktivace aminokyselin pro proteosyntézu
   - Syntéza NAD\u207a a dalších kofaktor\u016f

### Energetick\u00e1 bilance bu\u0148ky

Typick\u00e1 lidsk\u00e1 bu\u0148ka obsahuje:
- ~1 mM ATP (koncentrace)
- ~10\u2079 molekul ATP
- Obrat: cel\u00e9 mno\u017estv\u00ed ATP se spot\u0159ebuje a regeneruje ka\u017ed\u00e9 1-2 minuty

Lidsk\u00e9 t\u011blo denn\u011b:
- Spot\u0159ebuje a regeneruje ~40-70 kg ATP
- To odpov\u00edd\u00e1 ~500-700 mol ATP/den

## Purinergn\u00ed signalizace

### Objev a v\u00fdvoj konceptu

Purinergn\u00ed signalizace byla poprvé pops\u00e1na Geoffreym Burnstockem v roce 1972,
kdy navrhl existenci "purinergn\u00edch nerv\u016f" vyu\u017e\u00edvaj\u00edc\u00edch ATP jako neurotransmiter.
Po\u010d\u00e1te\u010dn\u00ed skepse byla p\u0159ekon\u00e1na a dnes je purinergn\u00ed signalizace uzn\u00e1v\u00e1na
jako jeden z nejroz\u0161\u00ed\u0159en\u011bj\u0161\u00edch sign\u00e1ln\u00edch systémů.

### P2X receptory (ionotropn\u00ed)

P2X receptory jsou ligand-\u0159\u00edzen\u00e9 iontov\u00e9 kan\u00e1ly aktivovan\u00e9 extracelul\u00e1rn\u00edm ATP:

| Receptor | Distribuce | Funkce | EC\u2085\u2080 ATP |
|----------|-----------|--------|---------|
| P2X1 | Hlad\u00e1 svalovina, trombocyty | Kontrakce c\u00e9v, agregace | ~1 \u00b5M |
| P2X2 | CNS, senzorické neurony | Neuromodulace | ~10 \u00b5M |
| P2X3 | Senzorické neurony, DRG | Nocirepce, chu\u0165 | ~1 \u00b5M |
| P2X4 | Mikroglie, endotel | Neuropatick\u00e1 bolest | ~1 \u00b5M |
| P2X5 | K\u016f\u017ee, st\u0159evo | Proliferace | ~10 \u00b5M |
| P2X6 | CNS | Heteromerizace | - |
| P2X7 | Imunitní bu\u0148ky, mikroglie | Z\u00e1n\u011bt, apopt\u00f3za | ~100 \u00b5M |

**Struktura P2X receptor\u016f:**
- Trimerní sestavení
- Ka\u017ed\u00e1 podjednotka: 2 transmembr\u00e1nov\u00e9 dom\u00e9ny
- Velk\u00e1 extracelul\u00e1rn\u00ed smy\u010dka s vazebným místem pro ATP
- Propustnost pro Na\u207a, K\u207a a v n\u011bkter\u00fdch p\u0159\u00edpadech Ca\u00b2\u207a

### P2Y receptory (metabotropn\u00ed)

P2Y receptory jsou receptory spřa\u017een\u00e9 s G-proteiny (GPCR):

| Receptor | G-protein | Druh\u00e1 poslov\u00e9 | Agonist\u00e9 |
|----------|----------|---------------|----------|
| P2Y1 | Gq/11 | IP\u2083, Ca\u00b2\u207a | ADP > ATP |
| P2Y2 | Gq/11 | IP\u2083, Ca\u00b2\u207a | ATP = UTP |
| P2Y4 | Gq/11 | IP\u2083, Ca\u00b2\u207a | UTP > ATP |
| P2Y6 | Gq/11 | IP\u2083, Ca\u00b2\u207a | UDP |
| P2Y11 | Gq/11, Gs | IP\u2083, cAMP | ATP |
| P2Y12 | Gi | \u2193cAMP | ADP |
| P2Y13 | Gi | \u2193cAMP | ADP |
| P2Y14 | Gi | \u2193cAMP | UDP-gluk\u00f3za |

### Ektonukleotid\u00e1zy

Extracelul\u00e1rn\u00ed ATP je rychle degradov\u00e1no ektonukleotid\u00e1zami:

1. **E-NTPDases (CD39 rodina)**
   - NTPDase1 (CD39): ATP/ADP \u2192 AMP
   - NTPDase2: ATP \u2192 ADP (preferenciálně)
   - NTPDase3: ATP/ADP \u2192 AMP (intermedi\u00e1rn\u00ed)

2. **E-NPP (nukleotid pyrofosfohydrol\u00e1zy)**
   - Hydrolyz\u00e1 fosfodiesterov\u00fdch vazeb

3. **5'-nukleotid\u00e1za (CD73)**
   - AMP \u2192 adenosin

4. **Alkalick\u00e1 fosfatáza**
   - Nespecifick\u00e1 defosforylace

Tento enzymov\u00fd syst\u00e9m konvertuje ATP postupn\u011b na adenosin, kter\u00fd aktivuje
vlastn\u00ed s\u00e9rii receptor\u016f (A1, A2A, A2B, A3).

## ATP v synaptick\u00e9m p\u0159enosu

### Uvoln\u011bn\u00ed ATP z neuron\u016f

ATP je uvoln\u011bn z neuron\u016f n\u011bkolika mechanismy:

1. **Vezikul\u00e1rn\u00ed exocyt\u00f3za**
   - Ulo\u017eení v synaptick\u00fdch vezikul\u00e1ch
   - Koncentrace v vezikul\u00e1ch: 100-500 mM
   - Kotr\u00e1nsmise s klasick\u00fdmi neurotransmitery
   - Transportér: VNUT (SLC17A9)

2. **Nevezikul\u00e1rn\u00ed uvoln\u011bn\u00ed**
   - Konexinové/panexinové hemikan\u00e1ly
   - Maxi-anion kan\u00e1ly
   - P2X7-indukovan\u00e1 permeabilizace
   - ABC transportéry

### Kotransmise

ATP funguje jako kotransmiter s mnoha klasick\u00fdmi neurotransmitery:

| Syst\u00e9m | Prim\u00e1rn\u00ed transmiter | Role ATP |
|---------|---------------------|----------|
| Sympat\u00edk | Noradrenalin | Rychl\u00e1 kontrakce c\u00e9v |
| Parasympat\u00edk | Acetylcholin | Modulace |
| Senzorické | Glutam\u00e1t | Nocicepce |
| Enter\u00edk | R\u016fzn\u00e9 | Inhibi\u010dn\u00ed junk\u010dn\u00ed potenci\u00e1ly |

**Sympati\u010dká neurotransmise:**
ATP a noradrenalin jsou ulo\u017eeny ve stejn\u00fdch vezikulch a uvoln\u011bny spole\u010dn\u011b.
ATP zp\u016fsobuje rychlou, přechodnou kontrakci (P2X1), zat\u00edmco noradrenalin
zaji\u0161\u0165uje pomalej\u0161\u00ed, udr\u017eovanou odpov\u011b\u010f (\u03b1-adrenergn\u00ed receptory).

### Synaptick\u00e1 plasticit

ATP moduluje synaptickou plasticitu n\u011bkolika mechanismy:

1. **Presynaptick\u00e1 modulace**
   - P2X receptory na presynaptick\u00fdch termin\u00e1lech
   - Modulace uvoln\u011bn\u00ed glutam\u00e1tu a GABA

2. **Postsynaptick\u00e1 modulace**
   - Interakce P2X s NMDA receptory
   - Modulace LTP (long-term potentiation)

3. **Gli\u00e1ln\u00ed zprost\u0159edkov\u00e1n\u00ed**
   - ATP z astrocyt\u016f ovliv\u0148uje synaptickou transmisi

## ATP a bolestiv\u00e1 signalizace

### Periferń nocicepce

ATP je kl\u00ed\u010dov\u00fdm medi\u00e1torem bolesti na periferii:

1. **Tkán\u011bv\u00e9 po\u0161kozen\u00ed**
   - Uvoln\u011bn\u00ed ATP z po\u0161kozen\u00fdch bun\u011bk
   - Koncentrace v extracelu\u00e1rn\u00edm prostoru: nM \u2192 µM-mM

2. **Aktivace nociceptor\u016f**
   - P2X3 receptory na senzori\u010dck\u00fdch neuronech (DRG)
   - P2X2/3 heteromery - pomal\u00e1 desensitizace
   - Rychl\u00e1 depolarizace a generace ak\u010dn\u00edch potenci\u00e1l\u016f

3. **Senzitizace**
   - P2Y receptory pot\u011bn\u00e1vaj\u00ed dal\u0161\u00ed nocicept\u00edvn\u00ed kan\u00e1ly
   - Interakce s TRPV1 a ASIC kan\u00e1ly

### Neuropatick\u00e1 bolest

P2X4 receptory na mikrogliích hr\u00e1j\u00ed kl\u00ed\u010dovou roli v neuropatick\u00e9 bolesti:

1. **Aktivace mikroglie**
   - Nervov\u00e9 po\u0161kozen\u00ed \u2192 upregulace P2X4 na mikrogliích
   - ATP z po\u0161kozen\u00fdch neuron\u016f aktivuje P2X4

2. **BDNF uvoln\u011bn\u00ed**
   - P2X4 aktivace \u2192 uvoln\u011bn\u00ed BDNF z mikroglie
   - BDNF p\u016fsob\u00ed na TrkB receptory na neuronech

3. **Disinhibice**
   - BDNF sni\u017euje sílu GABAergn\u00ed inhibice
   - V\u00fdsledek: centrální senzitizace a allod\u00fdnie

### Migr\u00e9na

ATP se pod\u00edl\u00ed na patofyziologii migrény:

- Uvoln\u011bn\u00ed z aktivovan\u00fdch trombocyt\u016f
- Aktivace trigeminov\u00e1skularn\u00edho syst\u00e9mu
- P2X3 receptory na trigminov\u00fdch neuronech

## ATP v gli\u00e1ln\u00ed komunikaci

### Astrocyty

Astrocyty jsou kl\u00ed\u010dov\u00fdmi hr\u00e1\u010di v purinergn\u00ed signalizaci:

1. **Uvoln\u011bn\u00ed ATP**
   - Exocytóza z lyzozom\u016f
   - Konexin 43 hemikan\u00e1ly
   - P2X7-indukovan\u00fd efflux

2. **Kalciové vlny**
   - ATP \u0161\u00ed\u0159\u00ed kalciov\u00e9 vlny mezi astrocyty
   - Regenerativn\u00ed uvoln\u011bn\u00ed ATP
   - Dosah: stovky µm

3. **Gliótransmise**
   - ATP z astrocyt\u016f moduluje synaptickou aktivitu
   - Konverze na adenosin - inhibi\u010dn\u00ed p\u016fsoben\u00ed

### Mikroglie

Mikroglie vyu\u017e\u00edvaj\u00ed purinergn\u00ed signalizaci pro:

1. **Chemotaxe**
   - ATP jako "find-me" sign\u00e1l
   - Gradient ATP \u0159\u00edd\u00ed migraci mikroglie k místu po\u0161kozen\u00ed

2. **Fagocyt\u00f3za**
   - P2Y6 receptory stimuluj\u00ed fagocyt\u00f3zu
   - UDP jako preferovaný ligand

3. **Z\u00e1n\u011bt**
   - P2X7 aktivuje NLRP3 inflam\u00e1zom
   - Uvoln\u011bn\u00ed IL-1\u03b2 a IL-18

### Oligodendrocyty

- P2X7 receptory mohou indukovat demyelinizaci
- P2Y1 receptory podporuj\u00ed diferenciaci prekurzor\u016f

## Farmakologie purinergn\u00edch receptor\u016f

### P2X antagonist\u00e9

| Slou\u010denina | Selektivita | Pou\u017eit\u00ed |
|------------|-------------|--------|
| TNP-ATP | P2X1, P2X3 | V\u00fdzkumn\u00fd n\u00e1stroj |
| A-317491 | P2X3, P2X2/3 | Anal\u00e9getik (preklin) |
| A-740003 | P2X7 | Antinociceptivn\u00ed |
| AF-353 (Gefapixant) | P2X3 | Chronick\u00fd ka\u0161el (klinick\u00e9) |

### P2Y modul\u00e1tory

| Slou\u010denina | Receptor | Typ | Pou\u017eit\u00ed |
|------------|----------|-----|--------|
| Clopidogrel | P2Y12 | Antagonista | Antitrombotikum |
| Prasugrel | P2Y12 | Antagonista | Antitrombotikum |
| Ticagrelor | P2Y12 | Antagonista | Antitrombotikum |
| Cangrelor | P2Y12 | Antagonista | i.v. antitrombotikum |
| Diquafosol | P2Y2 | Agonista | Such\u00e9 oko |

### Ektonukleotid\u00e1zové inhibitory

- AOPCP: inhibitor CD73
- POM-1: inhibitor NTPDase
- PSB-12379: selektivn\u00ed inhibitor NTPDase2

## Terapeutick\u00fd potenci\u00e1l

### Bolest

1. **P2X3/P2X2-3 antagonist\u00e9**
   - Gefapixant (MK-7264): schv\u00e1leno pro refrakt\u00e9rn\u00ed chronick\u00fd ka\u0161el
   - Eliapixant: ve v\u00fdvoji pro bolest mo\u010dov\u00e9ho měch\u00fd\u0159e

2. **P2X7 antagonist\u00e9**
   - V\u00fdzkum pro neuropatickou bolest
   - CE-224,535: f\u00e1ze II pro revmatoidn\u00ed artritidu

### Neurodegenerace

- **Alzheimerova choroba**: modulace mikrogli\u00e1ln\u00ed aktivace
- **Parkinsonova choroba**: P2X7 jako c\u00edl pro neuprotekci
- **ALS**: P2X7 antagonist\u00e9 ve v\u00fdvoji

### Kardiovaskulární choroby

- P2Y12 inhibitory: zlat\u00fd standard v antitrombotické terapii
- P2X1 antagonisté: potenci\u00e1l pro antitrombotika s men\u0161\u00edm krv\u00e1cen\u00edm

### Onkologie

- ATP jako protinn\u00e1dorov\u00fd agens (vysok\u00e9 d\u00e1vky)
- P2X7 jako c\u00edl pro imunoterapii
- CD73 inhibitory v kombinaci s checkpoint inhibitory

### Oftalmologie

- Diquafosol (P2Y2 agonista): such\u00e9 oko (schv\u00e1leno v Japonsku)
- P2Y2 agonist\u00e9 pro podporu sekrece slz

## V\u00fdzkumn\u00e9 perspektivy

### Nov\u00e9 sm\u011bry

1. **Alosterické modul\u00e1tory**
   - Jemn\u011bj\u0161\u00ed modulace ne\u017e orthosterické ligandy
   - Men\u0161\u00ed ne\u017e\u00e1douc\u00ed \u00fa\u010dinky

2. **Selektivn\u00ed c\u00edlen\u00ed subtryp\u016f**
   - Rozli\u0161en\u00ed homo- a heteromer\u016f P2X
   - Tkán\u011b specifick\u00e9 exprese

3. **Kombinovan\u00e9 p\u0159\u00edstupy**
   - Modulace ektonukleotid\u00e1z
   - Ovlivn\u011bn\u00ed purinergního tonu

4. **Biomarkery**
   - Extracelul\u00e1rn\u00ed ATP jako biomarker
   - Solu\u00c1biln\u00ed CD73 v diagnostice

### Metodologick\u00e9 v\u00fdzvy

- Rychl\u00e1 degradace ATP zt\u011b\u017euje m\u011b\u0159en\u00ed
- Pleiotropn\u00ed \u00fa\u010dinky komlikuj\u00ed interpretaci
- Pot\u0159eba lep\u0161\u00edch biosenzor\u016f

## Shrnut\u00ed

Adenosintrifosf\u00e1t (ATP) p\u0159edstavuje molekulu s v\u00fdji\u00e1me\u010dn\u00fdm dualistick\u00fdm
charakterem. Jako univerz\u00e1ln\u00ed energetick\u00e1 m\u011bna pohání v\u0161echny \u017eivotn\u00ed
procesy - od svalov\u00e9 kontrakce p\u0159es biosyn\u00e9zu makromolekul a\u017e po
aktivn\u00ed transport. Jako signáln\u00ed molekula a neurotransmiter pak ATP
zprost\u0159edkov\u00e1v\u00e1 komplexn\u00ed komunikaci mezi bu\u0148kami nervov\u00e9ho syst\u00e9mu.

Purinergn\u00ed signalizace prost\u0159ednictv\u00edm P2X a P2Y receptor\u016f se pod\u00edl\u00ed na
\u0161irok\u00e9m spektru fyziologick\u00fdch a patologick\u00fdch proces\u016f - od synaptick\u00e9
plasticity p\u0159es nocirepci a\u017e po neuroinflamaci. Objev t\u011bchto drah
otev\u0159el nov\u00e9 terapeutick\u00e9 mo\u017enosti, z nich\u017e n\u011bkter\u00e9 ji\u017e na\u0161ly
uplatn\u011bn\u00ed v klinick\u00e9 praxi (P2Y12 inhibitory, gefapixant), zat\u00edmco
jin\u00e9 jsou p\u0159edm\u011btem intenzivn\u00edho v\u00fdzkumu.

Pochopen\u00ed komplexn\u00ed s\u00edt\u011b purinergn\u00ed signalizace, v\u010detn\u011b role
ektonukleotid\u00e1z a konverze na adenosin, p\u0159edstavuje z\u00e1klad pro v\u00fdvoj
nov\u00fdch terapeutick\u00fdch strategi\u00ed c\u00edlen\u00fdch na bolest, neurodegenerativn\u00ed
onemocn\u011bn\u00ed, z\u00e1n\u011bt a dal\u0161\u00ed patologie.

## Reference

1. Burnstock G. Purinergic nerves. Pharmacol Rev. 1972;24(3):509-581.
2. Burnstock G. Purinergic signalling: from discovery to current developments. Exp Physiol. 2014;99(1):16-34.
3. Khakh BS, North RA. P2X receptors as cell-surface ATP sensors in health and disease. Nature. 2006;442(7102):527-532.
4. Abbracchio MP, et al. International Union of Pharmacology LVIII: update on the P2Y G protein-coupled nucleotide receptors. Pharmacol Rev. 2006;58(3):281-341.
5. Tsuda M, et al. P2X4 receptors induced in spinal microglia gate tactile allodynia after nerve injury. Nature. 2003;424(6950):778-783.
6. Zimmermann H, et al. Ectonucleotidases in the nervous system. Novartis Found Symp. 2006;276:113-128.
7. Idzko M, et al. Nucleotide signalling during inflammation. Nature. 2014;509(7500):310-317.
8. Di Virgilio F, et al. The P2X7 Receptor in Infection and Inflammation. Immunity. 2017;47(1):15-31.
